Long-term survival after neoadjuvant low-dose ipilimumab plus high-dose nivolumab in resectable stage III melanoma: the 5-year survival-update and biomarker analysis from the PRADO-trial

Autoría

autor: Michel W Wouters, Georgina V. Long, Kerwin F Shannon, Dirk J Grünhagen, Ellen Kapiteijn, Geke A P Hospers, Alexander C.J. van Akkooi, Karijn P. Suijkerbuijk, John B A G Haanen, Christian U Blank, Sydney Ch'ng, Robyn Saw, Joris B W Elbers, Richard Scolyer